Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$9.64 USD
+0.28 (2.99%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $9.64 0.00 (0.00%) 5:14 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNMD 9.64 +0.28(2.99%)
Will MNMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MNMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNMD
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy
MNMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
Other News for MNMD
Oppenheimer Reinstates Mind Medicine (MNMD) with Outperform Rating | MNMD Stock News
Mind Medicine (MNMD) Gains Positive Outlook with Oppenheimer's Outperform Rating
Mind Medicine resumed with an Outperform at Oppenheimer
Mind Medicine (MNMD) Upgraded by Oppenheimer with Promising MM120 Outlook
Mind Medicine upgraded at Oppenheimer on lead asset